06/27/23 8:00 AM EDT
|Title||In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU|
|Date and Time||06/27/23 8:00 AM EDT|
Hosted by Protalix Biotherapeutics (NYSE American: PLX)
WHERE: Lotte Palace Hotel, New York
Join us in-person for a KOL Breakfast with Protalix Biotherapeutics, discussing the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.
1. Ankit Mehta, MD, FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio® to address the unmet needs in Fabry disease.
A live question and answer session will follow the formal presentations.
For those unable to attend in-person, the event will be available via a live webcast.
You are required to register in advance for the event.
If you would like to ask a question during the live Q&A, please submit your request to firstname.lastname@example.org.